Stock analysis, price data, and AI-powered insights for Corvus Pharmaceuticals Inc (CRVS).
Corvus Pharmaceuticals Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for CRVS.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). CRVS Stock Intelligence Report. [stoxpulse.com/stocks/crvs]
Disclaimer: The information on this page about Corvus Pharmaceuticals Inc (CRVS) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Corvus Pharmaceuticals Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Corvus Pharmaceuticals to Host Investor and Analys...
14h ago
Watching Corvus Pharmaceuticals; CNBC Reports "Thi...
4d ago
StoxPulse AI results for CRVS: Pulse Score 52/100. Primary sentiment trends from 7 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$1.31B
P/E Ratio
—
EPS
$-0.12
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"
Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings
Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Friday
This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
12 Health Care Stocks Moving In Friday's Pre-Market Session
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40